Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Current Assets (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Current Assets for 4 consecutive years, with $52.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 17.88% to $52.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $52.1 million, a 17.88% increase, with the full-year FY2025 number at $52.1 million, up 17.88% from a year prior.
  • Current Assets was $52.1 million for Q4 2025 at Spruce Biosciences, up from $14.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $137.2 million in Q1 2023 to a low of $14.5 million in Q3 2025.
  • A 4-year average of $76.8 million and a median of $84.7 million in 2022 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 44.31% in 2023, then crashed 77.17% in 2025.
  • Spruce Biosciences' Current Assets stood at $83.6 million in 2022, then rose by 22.22% to $102.2 million in 2023, then tumbled by 56.74% to $44.2 million in 2024, then increased by 17.88% to $52.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Current Assets are $52.1 million (Q4 2025), $14.5 million (Q3 2025), and $21.0 million (Q2 2025).